Ask AI
ProCE Banner Series

Identify and Inform: Best Practices to Optimize Proficiency in the Assessment of HER2-Altered Solid Tumors

Join us in person or online for this interactive symposium in conjunction with USCAP 2026 in which a panel of pathologists and medical oncologists will discuss the nuances of HER2 testing across GI and lung cancers and the impact of testing results on treatment selection.

Please note that you must be registered for the USCAP Annual Meeting to attend in person. Registration is available at https://2026am.uscap.org/. If you would like to attend virtually, you may register below.

  AMA
Who Should Attend

This educational activity is intended for pathologists, oncologists, and other laboratory and healthcare professionals involved in the precision care of patients with HER2-altered solid tumors.

All Events

Identify and Inform: Best Practices to Optimize Proficiency in the Assessment of HER2-Altered Solid Tumors

Upcoming Events

March

25

2026

6:15 AM - 7:45 AM Central Time (CT)

In-person

Marriott Rivercenter San Antonio on the Riverwalk, 101 Bowie Street, San Antonio, Texas 78205

6:45 AM - 7:45 AM Central Time (CT)

Virtual

Topics

Gastrointestinal cancers
Lung cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in accurately performing pathological assessments for HER2 alterations, reporting results, and collaborating with the multidisciplinary team to personalize treatment for patients with HER2-altered solid tumors.

Target Audience
This educational activity is intended for pathologists, oncologists, and other laboratory and healthcare professionals involved in the precision care of patients with HER2-altered solid tumors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement pathological procedures to identify patients with solid tumors who may benefit from HER2-targeted therapy consistent with the latest guidelines and expert recommendations

  • Assess the clinical implications of accurate HER2 evaluation for patients with solid tumors based on the latest clinical trial evidence and FDA approvals

  • Apply evidence-based approaches to standardize HER2 scoring and reporting in clinical practice

  • Collaborate with the multidisciplinary team to optimize treatment strategies for patients with HER2-altered solid tumors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

American Board of Pathology Continuing Certification


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Continuing Certification Program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

For ABPath Lifelong Learning points, your information will be shared with the ABPath through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your Lifelong Learning points to appear on your ABPath records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191